Roche to Acquire Piramed for $160 Million, Adventrx Pharma Appoints Jose Hechavarria VP of Manufacturing, More

Piramed, a privately owned biotechnology company, signed a definitive agreement with Roche (Basel) that will result in Piramed being fully acquired for an upfront cash payment of $160 million plus a milestone payment of $15 million, which is due upon the commencement of Phase II clinical trials for the company's oncology program. Closing of the transaction is subject to standard conditions and reviews. Read More

Comments

Popular posts from this blog

Databases on the FDA Website

IPEXL - New Patent Search Tool

Employee Retention – A critical issue, why..and How to solve?